| 摘要 |
The present invention relates to a method employing Interferon Epsilon (IFNE1) as a therapeutic response, prognostic, or pharmacodynamic marker for cancer chemotherapeutic treatment involving the use of cyclin dependent kinase (CDK) inhibitors. The inventors have identified IFNE1 as a biomarker transcript that is upregulated when cancer cells are treated with CDK inhibitors. In an embodiment, the method of the invention includes measuring a level of IFNE1 mRNA or IFNE1 protein in a subject's tumor, blood or other tissue. An increase in the level of IFNE1 compared to control level can indicate that the CDK inhibitor has produced a therapeutic response or can determine whether a tumor is sensitive to a CDK inhibitor.
|
